MedTrace Logo

Treatment of Adults With Growth Hormone Deficiency

NCT00596037 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 136

Last updated 2012-10-05

No results posted yet for this study

Summary

The objective of this rollover study is to evaluate the long term (1 year) safety of a new weekly administered growth hormone preparation in adults with growth hormone deficiency who were treated with the same experimental preparation in study BPLG-005. In addition, further change in efficacy endpoints of BPLG-005 by prolonged treatment will be evaluated. Additional efficacy and safety data of the experimental preparation will be obtained from the switch-over patients.

Conditions

  • Pituitary Disorders
  • Adult Growth Hormone Deficiency

Interventions

DRUG

Growth hormone - LB03002

Sponsors & Collaborators

  • BioPartners GmbH

    collaborator INDUSTRY

  • LG Life Sciences

    lead INDUSTRY

Principal Investigators

  • HJ Ji, PhD · LG Life Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
23 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-08-31
Primary Completion
2008-09-30
Completion
2009-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00596037 on ClinicalTrials.gov